Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).

The American Journal of Cardiology
Xue-Qiao ZhaoB G Brown

Abstract

We examined the impact of metabolic syndrome (MS) on coronary stenosis progression and major cardiovascular (CV) events and investigated the mitigating effects of low-density lipoprotein (LDL) cholesterol lowering and LDL cholesterol lowering plus high-density lipoprotein (HDL) cholesterol increasing. This analysis combined individual patient data from 445 subjects who participated in 3 double-blinded, randomized, placebo-controlled trials (FATS, HATS, and AFREGS) comparing intensive lipid therapy to placebos on coronary stenosis progression by quantitative coronary angiography and on major CV events. The primary end points were change in mean proximal coronary diameter stenosis (Delta%S(prox)) over 3 years and the frequency of the predefined composite of coronary artery disease death, nonfatal myocardial infarction, stroke, and revascularization due to worsening ischemia. Patients with MS had 50% more rapid coronary stenosis progression and 64% increased CV event frequency compared to those without. More rapid coronary stenosis progression was significantly and independently associated with a 3.5-fold increased event risk (p <0.001). Combination lipid therapy significantly decreased stenosis progression by 83% (Delta%S(prox) 0...Continue Reading

References

Apr 1, 1993·Circulation·D WatersJ Lespérance
Dec 21, 2000·Current Atherosclerosis Reports·V S Kamanna, M L Kashyap
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Apr 30, 2003·Diabetes Care·Sander J RobinsUNKNOWN Veterans Affairs HDL Intervention Trial (VA-HIT)
Dec 29, 2005·Evidence-based Cardiovascular Medicine·L Friedman
Feb 8, 2007·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen

❮ Previous
Next ❯

Citations

Nov 17, 2010·Current Atherosclerosis Reports·Michael Clearfield
Nov 1, 2011·Current Atherosclerosis Reports·Todd C VillinesAllen J Taylor
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Kunal N BhattJefferson T Baer
Dec 15, 2011·Population Health Management·John F McAnaGeorge M Rapier
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
May 14, 2010·Current Opinion in Lipidology·Maneesh Vasant Udiawar, Alan Rees
Jul 4, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Shigemasa TaniAtsushi Hirayama
Oct 26, 2012·The American Journal of Clinical Nutrition·Fumiaki ImamuraDariush Mozaffarian
Jan 26, 2012·Indian Journal of Endocrinology and Metabolism·Panagiotis Anagnostis
May 14, 2010·Digestive Diseases and Sciences·Sombat TreeprasertsukKeith D Lindor
Feb 16, 2010·Pharmacology & Therapeutics·M John ChapmanPhilippe Giral
Nov 29, 2011·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Ramsey M DallalArthur Chernoff
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Jul 21, 2010·Current Opinion in Cardiology·Rajesh Tota-MaharajMichael J Blaha
Oct 12, 2011·Journal of Cardiovascular Medicine·Gian Francesco MuredduLeonardo De Luca
May 17, 2013·Journal of Clinical Pharmacology·Zhen ZhangZhong Zuo
Jan 28, 2020·Annual Review of Medicine·Ira J GoldbergEdward A Fisher
Mar 13, 2020·The Cochrane Database of Systematic Reviews·Patrizia NataleGiovanni Fm Strippoli
Jun 6, 2013·Current Opinion in Cardiology·Jonathan D SchofieldHandrean Soran
Aug 22, 2020·Journal of Lipid and Atherosclerosis·Eun-Jung RheeUNKNOWN Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis
Jul 6, 2019·The Korean Journal of Internal Medicine·Eun-Jung RheeIn-Kyung Jeong
Nov 26, 2011·Revista española de cardiología·Željko ReinerUNKNOWN Clinical Practice Guidelines Committee of the Spanish Society of Cardiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.